The Study of ICP-248 in Patients With Mature B-cell Malignancies
Status:
Not yet recruiting
Trial end date:
2026-10-30
Target enrollment:
Participant gender:
Summary
This is a Phase I study to evaluate the safety, tolerability, pharmacokinetics,
pharmacodynamics, and preliminary efficacy of ICP-248 in patients with mature B-cell
malignancies. This study consists of two parts: Part 1 dose-finding period and Part 2 dose
expansion period